Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 1×
“…activated receptor mutants, transforms cells in vitro (Di Fiore et al., 1987; DiMarco et al., 1989; Hudziak et al., 1987; Qian et al., 1995), and correlates with a poorer clinical outcome in some breast cancers and a variety of other malignancies (Slamon et al., 1987, 1989; Bacus et al., 1994).”
BackgroundStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Signal transduction by receptors with tyrosine kinase activity
Ullrich, A., & Schlessinger, J. (1990) · Cell · doi:10.1016/0092-8674(90)90801-k · Cited by 5,435 · cited 1×
“Although a number of soluble ligands have been identified for these three receptors, none has been identified for erbB2, which seems to be transactivated following heterodimerization (Ullrich and Schlessinger, 1990; Wada et al., 1990; Karunagaran et al., 1996; Stern and Kamps, 1988).”
BackgroundInfluentialCobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Tyrosine Kinase Inhibition: An Approach to Drug Development
Levitzki, A., & Gazit, A. (1995) · Science · doi:10.1126/science.7892601 · Cited by 1,635
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
Targeted Disruption of Mouse EGF receptor: Effect of Genetic Background on Mutant Phenotype
Threadgill, D. W., Dlugosz, A. A., Hansen, L. A., Tennenbaum, T., Lichti, U., Yee, D., LaMantia, C., Mourton, T., Herrup, K., Harris, R. C., et al. (1995) · Science · doi:10.1126/science.7618084 · Cited by 1,179
Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival
Grandis, J. R., Melhem, M. F., Gooding, W. E., Day, R., Holst, V. A., Wagener, M. M., Drenning, S. D., & Tweardy, D. J. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.824 · Cited by 1,113
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., & Yarden, Y. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5276 · Cited by 1,036
Cited by
Wang, J., Sánchez-Roselló, M., Aceña, J. L., del Pozo, C., Sorochinsky, A. E., Fustero, S., Soloshonok, V. A., & Liu, H. (2014) · Chemical Reviews · doi:10.1021/cr4002879 · Cited by 4,847
EGF–ERBB signalling: towards the systems level
Citri, A., & Yarden, Y. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1962 · Cited by 2,004
The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083
The Methylation Effect in Medicinal Chemistry
Barreiro, E. J., Kümmerle, A. E., & Fraga, C. A. M. (2011) · Chemical Reviews · doi:10.1021/cr200060g · Cited by 1,017
Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
Nahta, R., Yu, D., Hung, M.-C., Hortobagyi, G. N., & Esteva, F. J. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0509 · Cited by 916
Konecny, G. E., Pegram, M. D., Venkatesan, N., Finn, R., Yang, G., Rahmeh, M., Untch, M., Rusnak, D. W., Spehar, G., Mullin, R. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1182 · Cited by 914
Self-citationTreatment of HER2-positive breast cancer: current status and future perspectives
Arteaga, C. L., Sliwkowski, M. X., Osborne, C. K., Perez, E. A., Puglisi, F., & Gianni, L. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.177 · Cited by 861
Burris, H. A., Hurwitz, H. I., Dees, E. C., Dowlati, A., Blackwell, K. L., O'Neil, B., Marcom, P. K., Ellis, M. J., Overmoyer, B., Jones, S. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.584 · Cited by 619
Self-citationActivation of the PI3K/Akt pathway and chemotherapeutic resistance
West, K. A., Sianna Castillo, S., & Dennis, P. A. (2002) · Drug Resistance Updates · doi:10.1016/s1368-7646(02)00120-6 · Cited by 585
ErbB receptors: from oncogenes to targeted cancer therapies
Zhang, H., Berezov, A., Wang, Q., Zhang, G., Drebin, J., Murali, R., & Greene, M. I. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32278 · Cited by 574
The role of HER2 in cancer therapy and targeted drug delivery
Tai, W., Mahato, R., & Cheng, K. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.04.009 · Cited by 555
Arpino, G., Wiechmann, L., Osborne, C. K., & Schiff, R. (2008) · Endocrine Reviews · doi:10.1210/er.2006-0045 · Cited by 549
Phenotypic screening in cancer drug discovery — past, present and future
Moffat, J. G., Rudolph, J., & Bailey, D. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4366 · Cited by 507
Clinical pharmacokinetics of tyrosine kinase inhibitors
van Erp, N. P., Gelderblom, H., & Guchelaar, H.-J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.08.004 · Cited by 503
Spector, N. L., & Blackwell, K. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1507 · Cited by 497
Self-citationTargeting Tyrosine Kinases in Cancer: The Second Wave
Baselga, J. (2006) · Science · doi:10.1126/science.1125951 · Cited by 478
Targeting the ERBB family in cancer: couples therapy
Tebbutt, N., Pedersen, M. W., & Johns, T. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3559 · Cited by 466
Lin, N. U., Carey, L. A., Liu, M. C., Younger, J., Come, S. E., Ewend, M., Harris, G. J., Bullitt, E., Van den Abbeele, A. D., Henson, J. W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3588 · Cited by 456
Herceptin: mechanisms of action and resistance
Nahta, R., & Esteva, F. J. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.01.041 · Cited by 446
Challenges and Opportunities in Cancer Drug Resistance
Ward, R. A., Fawell, S., Floc’h, N., Flemington, V., McKerrecher, D., & Smith, P. D. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00383 · Cited by 445
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
Sharma, S. V., & Settleman, J. (2007) · Genes & Development · doi:10.1101/gad.1609907 · Cited by 441
HER2 therapy: Molecular mechanisms of trastuzumab resistance
Nahta, R., & Esteva, F. J. (2006) · Breast Cancer Research · doi:10.1186/bcr1612 · Cited by 433
Xia, W., Bacus, S., Hegde, P., Husain, I., Strum, J., Liu, L., Paulazzo, G., Lyass, L., Trusk, P., Hill, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602468103 · Cited by 374
Self-citationGefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255
Tracy, S., Mukohara, T., Hansen, M., Meyerson, M., Johnson, B. E., & Jänne, P. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1905 · Cited by 374
Rexer, B. N., & Arteaga, C. L. (2012) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v17.i1.20 · Cited by 370
Spector, N. L., Xia, W., Burris, H., Hurwitz, H., Dees, E. C., Dowlati, A., O'Neil, B., Overmoyer, B., Marcom, P. K., Blackwell, K. L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.157 · Cited by 362
Self-citationGomez, H. L., Doval, D. C., Chavez, M. A., Ang, P. C.-S., Aziz, Z., Nag, S., Ng, C., Franco, S. X., Chow, L. W. C., Arbushites, M. C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0590 · Cited by 338
Trastuzumab: triumphs and tribulations
Nahta, R., & Esteva, F. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210379 · Cited by 334
Ma, F., Ouyang, Q., Li, W., Jiang, Z., Tong, Z., Liu, Y., Li, H., Yu, S., Feng, J., Wang, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00108 · Cited by 334
Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression
Kaneda, M. M., Cappello, P., Nguyen, A. V., Ralainirina, N., Hardamon, C. R., Foubert, P., Schmid, M. C., Sun, P., Mose, E., Bouvet, M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1346 · Cited by 326
Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers
Widakowich, C., de Castro, G., de Azambuja, E., Dinh, P., & Awada, A. (2007) · The Oncologist · doi:10.1634/theoncologist.12-12-1443 · Cited by 324
McDermott, M., Eustace, A. J., Busschots, S., Breen, L., Crown, J., Clynes, M., O’Donovan, N., & Stordal, B. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00040 · Cited by 315
Role of ErbB Receptors in Cancer Cell Migration and Invasion
Appert-Collin, A., Hubert, P., Crémel, G., & Bennasroune, A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00283 · Cited by 310
Probing the Probes: Fitness Factors For Small Molecule Tools
Workman, P., & Collins, I. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.05.013 · Cited by 299
Burris, H. A. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_3-10 · Cited by 295
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
Schlam, I., & Swain, S. M. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00265-1 · Cited by 290
Wang, Y.-C., Morrison, G., Gillihan, R., Guo, J., Ward, R. M., Fu, X., Botero, M. F., Healy, N. A., Hilsenbeck, S. G., Phillips, G. L., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr3067 · Cited by 280
Sridhar, S. S., Seymour, L., & Shepherd, F. A. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01137-9 · Cited by 279
Rimawi, M. F., Mayer, I. A., Forero, A., Nanda, R., Goetz, M. P., Rodriguez, A. A., Pavlick, A. C., Wang, T., Hilsenbeck, S. G., Gutierrez, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.8027 · Cited by 274
Carnero, A. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210789941865 · Cited by 272
Nahta, R., Yuan, L. X. H., Du, Y., & Esteva, F. J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0423 · Cited by 267
“Lapatinib has been shown to inhibit baseline HER2 and EGFR signaling and to block signaling stimulated by the HER family ligands transforming growth factor (TGF)-a, heregulin, and epidermal growth factor (9, 15).”
BackgroundAgulnik, M., Cohen, E. W. E., Cohen, R. B., Chen, E. X., Vokes, E. E., Hotte, S. J., Winquist, E., Laurie, S., Hayes, D. N., Dancey, J. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8612 · Cited by 263
Xia, W., Gerard, C. M., Liu, L., Baudson, N. M., Ory, T. L., & Spector, N. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208774 · Cited by 258
Self-citationLiu, Q., Chang, J. W., Wang, J., Kang, S. A., Thoreen, C. C., Markhard, A., Hur, W., Zhang, J., Sim, T., Sabatini, D. M., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101144f · Cited by 257
Xia, W., Liu, L.-H., Ho, P., & Spector, N. L. (2004) · Oncogene · doi:10.1038/sj.onc.1207166 · Cited by 253
Self-citationDave, B., Migliaccio, I., Gutierrez, M. C., Wu, M.-F., Chamness, G. C., Wong, H., Narasanna, A., Chakrabarty, A., Hilsenbeck, S. G., Huang, J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.7814 · Cited by 252
“Recent in vitro data suggest that, unlike trastuzumab, loss of PTEN function is not associated with lapatinib resistance.(15) Previously, we observed in repeat biopsies of human primary breast cancers that blocking activation of the PI3K/AKT survival pathway is the main mechanism of action of trastuzumab.”
BackgroundBiology of Interactions: Antiepidermal Growth Factor Receptor Agents
Harari, P. M., Allen, G. W., & Bonner, J. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8984 · Cited by 214
HER2 aberrations in cancer: Implications for therapy
Yan, M., Parker, B. A., Schwab, R., & Kurzrock, R. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.02.008 · Cited by 210
“Lapatinib reversibly competes with ATP (Adenosine Triphosphate) in binding to the kinase domain of both HER2 and EGFR [28].”
BackgroundA reciprocal tensin-3–cten switch mediates EGF-driven mammary cell migration
Katz, M., Amit, I., Citri, A., Shay, T., Carvalho, S., Lavi, S., Milanezi, F., Lyass, L., Amariglio, N., Jacob-Hirsch, J., et al. (2007) · Nature Cell Biology · doi:10.1038/ncb1622 · Cited by 201
Self-citationLuque-Cabal, M., García-Teijido, P., Fernández-Pérez, Y., Sánchez-Lorenzo, L., & Palacio-Vázquez, I. (2016) · Clinical Medicine Insights: Oncology · doi:10.4137/cmo.s34537 · Cited by 179
Rowinsky, E. K. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.104433 · Cited by 178
Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation
Thomas, S. M., & Grandis, J. R. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.10.003 · Cited by 171
Scaltriti, M., Chandarlapaty, S., Prudkin, L., Aura, C., Jimenez, J., Angelini, P. D., Sánchez, G., Guzman, M., Parra, J. L., Ellis, C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3407 · Cited by 151
Lapatinib for Advanced or Metastatic Breast Cancer
Opdam, F. L., Guchelaar, H.-J., Beijnen, J. H., & Schellens, J. H. M. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0461 · Cited by 113
“This leads to downstream blocking of the mitogen-activated protein kinase and phosphatidylinositol 3-kinase, Akt, and mammalian target of rapamycin dependent transduction pathways, resulting in growth arrest or apoptosis of tumor cells [6, 7] (Fig.”
Background
Metadata
- Authors
- Xia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L.
- Venue
- Oncogene
- Published
- 2002-09-12
- Volume
- 21
- Issue
- 41
- Pages
- 6255-6263
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1982729445
- Cited by
- 664
- References
- 35
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.